HLA-A and non-small cell lung carcinoma: Within the cohort of Chinese NSCLC patients, L858R and HLA-A*33:03 coexist in 2.93% of patients while E746_A750del and HLA-A*11:01 cooccurred in 5.6% of the NSCLC patients [40].